Crosslinked Oxyntomodulin Analogs for Extended Half-Life
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Oxyntomodulin (OXM) analogs with short circulatory half-lives limit their clinical application for treating type 2 diabetes due to reduced potency when modified with PEG or lipid conjugates, necessitating high doses and limiting exploration of alternative delivery technologies.
Innovation Solution
Development of crosslinked OXM analogs with cysteine residues at specific positions, using crosslinking moieties like PEG, lipid groups, or fatty diacids, to enhance plasma stability and potency by extending half-life and improving receptor activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If PEG or lipid modified OXM analogs are used to extend circulatory half-life, then duration of action is improved, but potency is reduced
Solution Approach 1:
The patent applies parameter changes by modifying the molecular weight, composition, and structure of PEG conjugates (e.g., using different PEG chain lengths, architectures, and attachment positions) to optimize the balance between extended half-life and maintained potency. This includes exploring various PEG molecular weights and conjugation strategies to achieve the desired pharmacokinetic profile without sacrificing pharmacodynamic activity.
Solution Approach 2:
The patent employs composite materials by creating hybrid PEG-OXM conjugates that combine the peptide hormone OXM with polyethylene glycol chains. This composite structure allows the molecule to benefit from both the biological activity of OXM and the extended circulation properties of PEG, while the specific design of the composite (attachment site, PEG architecture) can be tuned to minimize potency loss.
2Duration of action of stationary object
If large doses of modified peptides are injected, then duration of action is maintained, but device complexity increases for alternative delivery technologies
Solution Approach 1:
The patent uses parameter changes to optimize the dose size and frequency by adjusting PEG conjugate characteristics. By finding the optimal balance between half-life extension and potency retention, the required dose can be minimized, making the therapy compatible with simpler delivery technologies like microneedles or nanoparticles that have size and dose constraints.
3Reliability
If crosslinking is used to enhance plasma stability, then reliability is improved, but manufacturing precision requirements increase
Solution Approach 1:
The patent employs an intermediary approach by using site-specific cysteine residues as intermediaries for crosslinking. These predetermined cysteine positions serve as controlled reaction sites that facilitate precise crosslinking with minimal variability. The cysteines act as mediators between the PEG conjugate and the peptide backbone, enabling controlled crosslinking chemistry that reduces manufacturing complexity compared to non-specific crosslinking methods.
Data Source
AI summary
Provided are oxyntomodulin analogs. The peptide analogs have at least two cysteines. The two cysteines are separated by six amino acids such that they can be crosslinked using suitable crosslinking moieties. The crosslinked peptides have long half-lives and/or efficacy. For example, peptide analog compositions are used for inducing weight loss and/or reducing blood glucose levels.